TapImmune Announces Progress in Phase II Trial

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

TapImmune Inc. said Memorial Sloan Kettering Cancer Center successfully completed the first safety cohort in its phase II ovarian cancer study.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

EC granted marketing authorization for Elahere (mirvetuximab soravtansine) for the treatment of adult patients with folate receptor-alpha positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three prior systemic treatment regimens. Elahere is the first and only folate receptor alpha-directed antibody drug conjugate medicine approved in the EU, as well as Iceland, Liechtenstein, Norway, and Northern Ireland.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login